

Literatur zum Artikel:

Patientensteuerung und Primärarztsystem

G. Wittinger, L. Sundmacher 2025: Primärarztsysteme im internationalen Vergleich: Wie gestalten andere Länder ihre Versorgung und was kann Deutschland davon lernen? MVF 04/2025

Robert Bosch Stiftung (2015): Gesundheitszentren für Deutschland: Wie ein Neustart in der Primärversorgung gelingen kann. Online verfügbar unter https://www.bosch-stiftung.de/sites/default/files/publications/pdf/2021-05/Studie_Primaerversorgung_Gesundheitszentren-fuer-Deutschland.pdf

Deutsches Ärzteblatt (2024): Was Deutschland vom finnischen Gesundheitssystem lernen könnte. Online verfügbar unter [https://www.aerzteblatt.de/news/was-deutschland-vom-finnischen-gesundheitssystem-lernen-koennte-](https://www.aerzteblatt.de/news/was-deutschland-vom-finnischen-gesundheitssystem-lernen-koennte-44f6148a-03bf-43b7-b994-2613210cd1bb)

44f6148a-03bf-43b7-b994-2613210cd1bb

AOK Baden-Württemberg: Vertrag zur Hausarztzentrierten Versorgung in Baden-Württemberg vom 08.05.2008 in der Fassung vom 01.11.2024 gemäß § 73 b SGB V. 2024

Bundesamt für Justiz: Sozialgesetzbuch (SGB) Fünftes Buch (V) – Gesetzliche Krankenversicherung – (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477) § 73 b Hausarztzentrierte Versorgung. Online verfügbar unter https://www.gesetze-im-internet.de/sgb_5/_73b.html

CDU (2025): Koalitionsvertrag 2025: Verantwortungsvolle Außenpolitik. Online verfügbar unter [https://www.cdu.de/ak-](https://www.cdu.de/aktuelles/koalitionsvertrag-2025-verantwortungs-volle-aussenpolitik/)

tuelles/koalitionsvertrag-2025-verantwortungs-volle-aussenpolitik/, zuletzt aktualisiert am 17.04.2025

Gerlach, Ferdinand M.; Szecsenyi, Joachim (2011): Hausarztzentrierte Versorgung. Inhalte und Qualität sind entscheidend. In: Deutsches Ärzteblatt 108, S. 996–998

Hausärztinnen- und Hausärzteverband (2025a): Hausarztverträge. Online verfügbar unter <https://www.haev.de/themen/hausarztvertraege>

World Health Organization (WHO): Integrated primary care for UHC. Online verfügbar unter <https://www.who.int/teams/integrated-health-services/clinical-services-and-systems/primary-care>

Literatur zum Artikel:

Fettlebererkrankungen

von Prof. Dr. med. Elke Roeb, MHAC

- [1] Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C et al: [Not Available]. *Z Gastroenterol* 2024, 62(7):1077–1087.
- [2] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L: The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology* 2023, 77(4):1335–1347.
- [3] Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C et al: [Not Available]. *Z Gastroenterol* 2022, 60(9):1346–1421.
- [4] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L: The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023 Apr 1;77(4):1335–1347
- [5] Du K, Wang L, Jun JH, Dutta RK, Maeso-Díaz R, Oh SH, Ko DC, Diehl AM: Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress. *Nat Aging* 2024, 4(7):949–968.
- [6] Israelsen M, Francque S, Tsochatzis EA, Krag A: Steatotic liver disease. *Lancet* 2024, 404(10464):1761–1778.
- [7] Berg T, Aehling NF, Bruns T, Welker MW, Weismüller T, Trebicka J, Tacke F, Strnad P, Sterneck M, Settmacher U et al: [Not Available]. *Z Gastroenterol* 2024, 62(9):1397–1573.
- [8] Loomba R, Friedman SL, Shulman GI: Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell* 2021, 184(10):2537–2564.
- [9] Shang Y, Grip ET, Modica A, Skröder H, Ström O, Ntanos F, Gudbjörnsdóttir S, Hagström H: Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes. *Diabetes Care* 2024, 47(6):978–985.
- [10] Vilar-Gomez E, Nephew LD, Vuppalandhi R, Gawrieh S, Mladenovic A, Pike F, Samala N, Chalasani N: High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. *Hepatology* 2022, 75(6):1491–1506.
- [11] Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El-Serag HB: Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. *Hepatology* 2020, 71(3):808–819.
- [12] Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, Buring JE, Chan AT, Chong DQ, Doody MM et al: Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. *Br J Cancer* 2018, 118(7):1005–1012.
- [13] Abdel-Rahman O, Helbling D, Schöb O, Eltobgy M, Mohamed H, Schmidt J, Giryas A, Mehrabi A, Iype S, John H et al: Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. *J Evid Based Med* 2017, 10(4):245–254.
- [14] Roeb E: Fettleber vorbeugen und behandeln für Dummies, vol. 1. Edition (6. November 2024): Herausgeber: Wiley-VCH; 2025.
- [15] Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, Rein M, Serfaty D, Kenigsbuch S, Zelicha H et al: The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. *J Hepatol* 2019, 71(2):379–388.
- [16] Roeb E, Weiskirchen R: Fructose and Non-Alcoholic Steatohepatitis. *Front Pharmacol* 2021, 12:634344.
- [17] Stricker S, Rudloff S, Geier A, Steveling A, Roeb E, Zimmer KP: Fructose Consumption-Free Sugars and Their Health Effects. *Dtsch Arztebl Int* 2021, 118(5):71–78.
- [18] Roeb E, Geier A: Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. *Z Gastroenterol* 2019, 57(4):508–517.
- [19] Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratz V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med*. 2025 Jun 5;392(21):2089–2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.

- [20] Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y et al: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *N Engl J Med* 2024, 391(4):299–310.
- [21] Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME et al: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. *N Engl J Med* 2024, 390(6):497–509.
- [22] Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, Gogia S, Sheikh MY, Behling C, Bedossa P et al: Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Gastroenterol Hepatol* 2023, 8(12):1080–1093.
- [23] Schmid A, Arians M, Burg-Roderfeld M, Karrasch T, Schäffler A, Roderfeld M, Roeb E: Circulating Adipokines and Hepatokines Serve as Diagnostic Markers during Obesity Therapy. *Int J Mol Sci* 2022, 23(22).
- [24] Schmid A, Arians M, Karrasch T, Pons-Kühnemann J, Schäffler A, Roderfeld M, Roeb E: Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. *J Clin Med* 2022, 11(7).
- [25] Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E, Guidone C, Angelini G, Pennestrì F, Sessa L et al: Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. *Lancet* 2023, 401(10390):1786–1797.

Literatur zum Artikel:

Cannabiskonsum in der Schwangerschaft: Neue Daten belegen Gefährdung des Kindes

von Dr. med. Deborah Scholz-Hehn, Dr. med. Mathias Luderer und Dr. med. Siegmund Drexler

- [1] Bespalova, N., Bunt, G., & Hill, K. P. (2024). Cannabis and Pregnancy. *Current Psychiatry Reports*, 26(11), 643–649.
- [2] Dellazizzo, L., Potvin, S., Giguère, S., & Dumais, A. (2022). Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: A systematic meta-review of meta-analyses. *Addiction*, 117(7), 1857–1870.
- [3] Gomes, T. M., da Silva, D. D., Carmo, H., Carvalho, F., & Silva, J. P. (2020). Epigenetics and the endocannabinoid system signaling: An intricate interplay modulating neurodevelopment. *Pharmacological Research*, 162, 105237.
- [4] Gunn, J. K. L., Rosales, C. B., Center, K. E., Nuñez, A., Gibson, S. J., Christ, C., & Ehiri, J. E. (2021). Prenatal cannabis exposure and infant outcomes: Overview of studies and future directions. *Addiction*, 116(3), 525–536. <https://doi.org/10.1111/add.15467>
- [5] Hayes, S., Delker, E., & Bandoli, G. (2023). The prevalence of cannabis use reported among pregnant individuals in the United States is increasing, 2002–2020. *Journal of Perinatology*, 43(3), 387–389.
- [6] Jenkins, B. W., Moore, C. F., Jantzie, L. L., & Weerts, E. M. (2025). Prenatal cannabinoid exposure and the developing brain: evidence of lasting consequences in preclinical rodent models. *Neuroscience & Biobehavioral Reviews*, 106207.
- [7] Lo, J. O., Ayers, C. K., Yeddala, S., Shaw, B., Robalino, S., Ward, R., & Kansagara, D. (2025). Prenatal Cannabis Use and Neonatal Outcomes: A Systematic Review and Meta-Analysis. *JAMA pediatrics*.
- [8] Marchand, G., Masoud, A. T., Govindan, M., Ware, K., King, A., Ruth, S., ... & Sainz, K. (2022). Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. *JAMA Network Open*, 5(1), e2145653–e2145653.
- [9] Olderbak, S., Möckl, J., Manthey, J., Lee, S., Rehm, J., Hoch, E., & Kraus, L. (2024). Trends and projection in the proportion of (heavy) cannabis use in Germany from 1995 to 2021. *Addiction*, 119(2), 311–321.
- [10] Paul, S. E., Hatoum, A. S., Fine, J. D., Johnson, E. C., Hansen, I., Karcher, N. R., ... & Bogdan, R. (2021). Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD study. *JAMA Psychiatry*, 78(1), 64–76.
- [11] Rodrigues, R. J., Marques, J. M., & Köfalvi, A. (2024). Cannabis, endocannabinoids and brain development: from embryogenesis to adolescence. *Cells*, 13(22), 1875.
- [12] Scheyer, A. F., Melis, M., Trezza, V., & Manzoni, O. J. (2019). Consequences of perinatal cannabis exposure. *Trends in Neurosciences*, 42(12), 871–884.
- [13] Young-Wolff, K. C., Slama, N. E., Avalos, L. A., Padon, A. A., Silver, L. D., Adams, S. R., ... & Alexeeff, S. E. (2024, November). Cannabis use during early pregnancy following recreational cannabis legalization. In *JAMA Health Forum* (Vol. 5, No. 11, pp. e243656–e243656). American Medical Association.